» Articles » PMID: 26008937

Achieving Patient Engagement in Multiple Sclerosis: A Perspective from the Multiple Sclerosis in the 21st Century Steering Group

Abstract

While advances in medicine, technology and healthcare services offer promises of longevity and improved quality of life (QoL), there is also increasing reliance on a patient׳s skills and motivation to optimize all the benefits available. Patient engagement in their own healthcare has been described as the 'blockbuster drug of the century'. In multiple sclerosis (MS), patient engagement is vital if outcomes for the patient, society and healthcare systems are to be optimized. The MS in the 21st Century Steering Group devised a set of themes that require action with regard to patient engagement in MS, namely: 1) setting and facilitating engagement by education and confidence-building; 2) increasing the importance placed on QoL and patient concerns through patient-reported outcomes (PROs); 3) providing credible sources of accurate information; 4) encouraging treatment adherence through engagement; and 5) empowering through a sense of responsibility. Group members independently researched and contributed examples of patient engagement strategies from several countries and examined interventions that have worked well in areas of patient engagement in MS, and other chronic illnesses. The group presents their perspective on these programs, discusses the barriers to achieving patient engagement, and suggests practical strategies for overcoming these barriers. With an understanding of the issues that influence patient engagement in MS, we can start to investigate ways to enhance engagement and subsequent health outcomes. Engaging patients involves a broad, multidisciplinary approach.

Citing Articles

Self-management Interventions in Multiple Sclerosis: Case Series from a Tertiary Neuroscience Hospital.

D Keerthana , Arun M, Kumar G, Desai G, Thomas P, Netravathi M Indian J Psychol Med. 2024; :02537176241264772.

PMID: 39564228 PMC: 11572388. DOI: 10.1177/02537176241264772.


TAURUS-MS II: real-world use of teriflunomide in Germany and changes in treatment patterns over time.

Kallmann B, Zu Eulenburg G, Kullmann J, Maurer M Ther Adv Neurol Disord. 2024; 17:17562864241252722.

PMID: 38808094 PMC: 11131407. DOI: 10.1177/17562864241252722.


Subjective Rationalities of Nonadherence to Treatment and Vaccination in Healthcare Decision-Making.

Turja T, Rosenlund M, Kuusisto H Patient Prefer Adherence. 2024; 18:821-826.

PMID: 38623311 PMC: 11017982. DOI: 10.2147/PPA.S454661.


Identifying definite patterns of unmet needs in patients with multiple sclerosis using unsupervised machine learning.

Maida E, Abbadessa G, Cocco E, Valentino P, Lerede A, Frau J Neurol Sci. 2024; 45(7):3333-3345.

PMID: 38388897 PMC: 11176240. DOI: 10.1007/s10072-024-07416-9.


Association analysis between symptomology and herpesvirus IgG antibody concentrations in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and multiple sclerosis.

Domingues T, Malato J, Grabowska A, Lee J, Ameijeiras-Alonso J, Biecek P Heliyon. 2023; 9(7):e18250.

PMID: 37519635 PMC: 10372404. DOI: 10.1016/j.heliyon.2023.e18250.